Abstract
A large positive BeAM value (difference between bedtime [Be] and next-day pre-breakfast [AM] glucose) may indicate to physicians when prandial therapy needs to be added and further titration of basal insulin should be ceased. This study explores whether the addition of the GLP-1 receptor agonist lixisenatide (LIXI) has a greater impact than placebo (PBO) on the reduction of BeAM value when added as prandial therapy to basal insulin in type 2 diabetes mellitus (T2DM) patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
